Nepadutant

Tachykinin NK2 Receptor Antagonist PeptideRx: InvestigationalCompound: Investigational

Also known as: MEN 11420, MEN-11420, N-9, Nepadutant

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Source Nepadutant at Peptiology

Save 10% with code PEPTI-BOSSRABBIT-10

Shop Now & Save 10% →

Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.

Summary

Nepadutant is a synthetic peptide antagonist of the NK2 tachykinin receptor that has been evaluated in clinical trials for asthma, irritable bowel syndrome, and chronic pain. It has not received regulatory approval.

Mechanism of Action

Competitive antagonist at neurokinin‑2 (NK2) receptors, blocking tachykinin‑mediated smooth‑muscle contraction and neurogenic inflammation

Routes of Administration

IntravenousOralSubcutaneous

Goals & Uses

  • Visceral PainPain / GastroenterologyModerate
  • Asthma / BronchoconstrictionRespiratoryLow
  • Chronic PainPainLow
  • Irritable Bowel SyndromeGastrointestinalModerate
  • Irritable Bowel Syndrome (IBS)GastrointestinalModerate
  • Infantile ColicGastrointestinal / PediatricLow
  • AsthmaRespiratoryModerate

Contraindications

  • Hypersensitivity to nepadutant or excipientsAllergyHigh
  • Known hypersensitivity to nepadutantAllergyHigh

Adverse Effects

  • Injection site reactionsLocalUncommon
  • HeadacheNeurologicUncommonPain in the head or upper neck
  • Gastrointestinal discomfortGastrointestinalUncommon
  • Injection site erythemaLocalCommonRedness at the injection site

Drug Interactions

  • Beta‑agonistsLow
  • CYP3A4 substrates / inhibitorsLow

Population Constraints

  • PregnancyReproductive SafetyRelative
  • Pediatric populations (neonates/infants)AgeRelative
  • Severe hepatic impairmentOrgan ImpairmentRelative

Regulatory Status

  • European UnionInvestigationalClinical development discontinued.
  • United StatesInvestigationalPhase II completed, no NDA filed.
  • United KingdomInvestigationalNo MHRA approval; remains investigational

No approved indication; development halted after Phase II trials due to limited efficacy.

Evidence & Sources

No sources recorded yet.

Frequently Asked Questions

What is Nepadutant?

Nepadutant is a synthetic peptide antagonist of the NK2 tachykinin receptor that has been evaluated in clinical trials for asthma, irritable bowel syndrome, and chronic pain. It has not received regulatory approval.

What is Nepadutant used for?

Nepadutant is educationally associated with: Visceral Pain, Asthma / Bronchoconstriction, Chronic Pain, Irritable Bowel Syndrome, Irritable Bowel Syndrome (IBS), Infantile Colic, Asthma. Educational only — not medical advice.

How is Nepadutant administered?

Recorded routes of administration: Intravenous, Oral, Subcutaneous.

What are the potential side effects of Nepadutant?

Reported adverse effects include: Injection site reactions, Headache, Gastrointestinal discomfort, Injection site erythema. This list is not exhaustive — consult a qualified clinician.

Who should avoid Nepadutant?

Recorded contraindications: Hypersensitivity to nepadutant or excipients, Known hypersensitivity to nepadutant. Consult a qualified clinician before use.

More in this class